About 188,422 results

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

The treatment of motor manifestations of Parkinson's disease (PD) is essentially a trade-off between adequate relief of motor symptoms and prevention and control of motor complications, particularly levodopa-induced dyskinesia (LID). Progression of PD is paralleled by a progressive difficulty in achieving the balance. Functional neurosurgical procedures provide sustained relief of LID in carefu...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Lung ultrasound monitoring in patients with COVID-19 on home isolation

Many patients with COVID-19, the clinical illness caused by SARS-CoV-2 infection, exhibit mild symptoms and do not require hospitalization. Instead, these patients are often referred for 14-days of home isolation as symptoms resolve. Lung ultrasound is well-established as an important means of evaluating lung pathology in patients in the emergency department and in intensive care units. Ultraso...

Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications
Frontiers in Neurology;

Dec 14th, 2014 - The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson’s disease (PD) for over 40 years. However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Parkinson's Disease;

May 28th, 2013 - Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskin...

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

Pembrolizumab Increases 24-Month PFS2 in PD-L1+ HNSCC

May 29th, 2020 - Patients with PD-L1-positive relapsed/refractory head and neck squamous cell carcinoma (HNSCC) who were treated in the KEYNOTE-048 trial experienced and improvement in progression-free survival after subsequent therapy (PFS2) with pembrolizumab (Keytruda) compared with the EXTREME regimen. The PFS2 benefit was consistent in patients who received pembrolizumab alone and those who received added ...

Tivozanib Confirmed Superior to Sorafenib For Treatment of Refractory Metastatic RCC

May 28th, 2020 - In the phase II TIVO-3 trial, treatment with tivozanib (Fotivda) in patients with highly relapsed or refractory metastatic renal cell carcinoma (RCC) significantly improved progression-free survival (PFS) compared with sorafenib (Nexavar) and demonstrated a similar overall survival (OS), according to results presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific P...

Responses to Olaparib/Cediranib Combination in Ovarian Cancer Warrant Further Investigation

May 28th, 2020 - Phase 3 trial results demonstrated comparable activity of cediranib and olaparib (Lynparza) with standard-of-care platinum-based chemotherapy in the treatment of recurrent platinum-sensitive ovarian cancer, despite missing the primary end point of progression-free survival (PFS) improvement. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific P...

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 29th, 2020 - The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) continued to demonstrate a clinically significant improvement in progression-free and overall survival (OS) compared with sunitinib (Sutent) in patients with previously untreated, advanced renal cell carcinoma (RCC), according to updated findings of the phase 3 KEYNOTE-426 trial that were presented during the 2020 ASCO Virtual Sc...

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

May 29th, 2020 - Treatment with pembrolizumab (Keytruda) induced a 4.9-month progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed/refractory classical Hodgkin lymphoma, according to findings presented at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms

Parkinson’s disease (PD) is a multi-attribute neurodegenerative disorder combining motor and nonmotor symptoms without well-defined diagnostic clinical markers. The presence of primary motor features (bradykinesia, rest tremor, rigidity and loss of postural reflexes) are the most characteristic signs of PD that are also utilized to identify patients in current clinical practice. The successful ...

The clinical symptoms of Parkinson's disease
Journal of Neurochemistry;

In this review, the clinical features of Parkinson's disease, both motor and non‐motor, are described in the context of the progression of the disease. Also briefly discussed are the major treatment strategies and their complications.

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC

May 29th, 2020 - Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma

May 28th, 2020 - The chimeric antigen receptor (CAR) T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial. Lead author Jesus G. Berdeja, MD, reported that the overall response rate (ORR) was 100%, with a stringent complete response (...

Selinexor Triplet Improves Response, Reduces Neuropathy in Relapsed/Refractory Multiple Myeloma

May 28th, 2020 - When added to bortezomib (Velcade) and dexamethasone in patients with multiple myeloma, selinexor (Xpovio), an inhibitor of XPO1-mediated nuclear export, improves progression-free survival (PFS) and overall response rate (ORR) and reduces the incidence of peripheral neuropathy.

Cediranib/Olaparib Combo Yields Comparable Results to Chemo in Ovarian Cancer Treatment

May 28th, 2020 - A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.